Hims & Hers disrupts legacy healthcare distribution
The bull case presented for Hims & Hers is that the company is structurally bypassing legacy PBMs, insurance, and reimbursement networks to deliver healthcare directly to consumers.
The argument
The guest argued that the US healthcare system is paternalistic and convoluted, whereas consumer channels like Hims & Hers offer price transparency, on-demand access, and complete choice. He asserted that this direct-to-consumer model aligns company incentives with patient outcomes because customers only pay if they are satisfied and healthy.
The thesis, stress-tested
✓ What validates it
- ✓Acceleration of consumer adoption of GLP-1s and other treatments through the platform over the next five years
- ✓Successful margin expansion as lab testing and other offerings are verticalized
▸ Risks discussed
- ▸Regulatory pressure and friction from established drug and diagnostic companies
- ▸High initial costs and low margins from verticalizing infrastructure like lab testing
Hear it yourself
"All of it, or as much of it as possible, will go through consumer channels like Hims and Hers, where you can pick up your phone, have on demand access, have total price transparency, have complete choice of which doctor, which specialists, which treatment, complete information access, and then control."
00:00 / 00:19
AFFILIATE LINK · ZORTIX MAY EARN A COMMISSION · NEVER A RECOMMENDATION TO TRADE